Symbols / CAPR
CAPR Chart
About
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.54B |
| Enterprise Value | 1.19B | Income | -81.99M | Sales | 11.13M |
| Book/sh | 1.83 | Cash/sh | 2.16 | Dividend Yield | — |
| Payout | 0.00% | Employees | 160 | IPO | — |
| P/E | — | Forward P/E | 186.89 | PEG | — |
| P/S | 138.31 | P/B | 15.43 | P/C | — |
| EV/EBITDA | -14.04 | EV/Sales | 107.09 | Quick Ratio | 3.50 |
| Current Ratio | 3.59 | Debt/Eq | 17.34 | LT Debt/Eq | — |
| EPS (ttm) | -1.75 | EPS next Y | 0.15 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-19 | ROA | -49.39% |
| ROE | -107.79% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -7.79% | Profit Margin | 0.00% | Shs Outstand | 54.40M |
| Shs Float | 40.83M | Short Float | 11.97% | Short Ratio | 4.34 |
| Short Interest | — | 52W High | 40.37 | 52W Low | 4.30 |
| Beta | 0.40 | Avg Volume | 2.78M | Volume | 196.01K |
| Target Price | $50.80 | Recom | None | Prev Close | $27.91 |
| Price | $28.30 | Change | 1.40% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$50.80
Mean price target
2. Current target
$27.91
Latest analyst target
3. DCF / Fair value
$-12.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$27.91
Low
$41.00
High
$62.00
Mean
$50.80
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-15 | reit | B. Riley Securities | Buy → Buy | $50 |
| 2025-12-10 | reit | Piper Sandler | Overweight → Overweight | $45 |
| 2025-12-08 | main | Oppenheimer | Outperform → Outperform | $54 |
| 2025-12-04 | main | Maxim Group | Buy → Buy | $50 |
| 2025-12-03 | main | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-11-12 | main | Roth Capital | Buy → Buy | $13 |
| 2025-09-25 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-09-11 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-07-14 | main | Roth Capital | Buy → Buy | $12 |
| 2025-07-11 | main | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-06-26 | init | B. Riley Securities | — → Buy | $21 |
| 2025-06-25 | main | Jones Trading | Buy → Buy | $29 |
| 2025-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $77 |
| 2025-06-23 | main | Oppenheimer | Outperform → Outperform | $22 |
| 2025-06-17 | reit | Roth Capital | Buy → Buy | $31 |
| 2025-06-13 | reit | HC Wainwright & Co. | Buy → Buy | $77 |
| 2025-05-14 | reit | Cantor Fitzgerald | Overweight → Overweight | $30 |
| 2025-03-20 | reit | Cantor Fitzgerald | Overweight → Overweight | $30 |
| 2025-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $77 |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $77 |
- Duchenne trial to showcase Deramiocel Phase 3 data at 2026 MDA meeting - Stock Titan ue, 24 Feb 2026 14
- CAPR stock rallied nearly 30% so far this week — here’s the February FDA catalyst investors are betting on - MSN Fri, 20 Feb 2026 15
- Capricor Therapeutics (CAPR) Deepens Its Exosome Bet: Strategic Edge or Concentration Risk? - simplywall.st ue, 24 Feb 2026 11
- CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On - Stocktwits hu, 19 Feb 2026 21
- Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unveiling a 74% Potential Upside in the Biotech Arena - DirectorsTalk Interviews Sat, 21 Feb 2026 05
- CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know - Yahoo Finance Fri, 05 Dec 2025 08
- Capricor Therapeutics Stock (CAPR) Opinions on HOPE-3 Trial Results | CAPR Stock News - Quiver Quantitative Wed, 03 Dec 2025 08
- CAPR Stock Price Prediction: Will CAPR Stock Price Hold Its 500% Surge? - Bitget hu, 04 Dec 2025 08
- CAPR Stock News: Investors with Large Losses Should Contact Robbins LLP to Learn About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit - PR Newswire ue, 12 Aug 2025 07
- Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits Mon, 23 Feb 2026 09
- Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory - Yahoo Finance hu, 18 Dec 2025 08
- Capricor Therapeutics (NASDAQ: CAPR) Phase 3 HOPE-3 Meets Skeletal, Cardiac Goals in DMD - Stock Titan Wed, 03 Dec 2025 08
- Capricor Therapeutics (NASDAQ: CAPR) prices 6M-share offering at $25, targeting $150M - Stock Titan Fri, 05 Dec 2025 08
- Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains? - Yahoo Finance Fri, 26 Sep 2025 07
- A Look At Capricor Therapeutics (CAPR) Valuation After Its New Shelf Registration Filing - simplywall.st Wed, 04 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3000 | 4170 | — | Conversion of Exercise of derivative security at price 1.39 per share. | DUNBAR GEORGE W JR | Director | — | 2025-12-19 00:00:00 | D |
| 1 | 750 | 1042 | — | Conversion of Exercise of derivative security at price 1.39 per share. | DUNBAR GEORGE W JR | Director | — | 2025-03-03 00:00:00 | D |
| 2 | 25000 | 34750 | — | Conversion of Exercise of derivative security at price 1.39 per share. | LITVACK FRANK I | Director | — | 2025-03-03 00:00:00 | D |
| 3 | 25000 | 34750 | — | Conversion of Exercise of derivative security at price 1.39 per share. | MARBAN LINDA | Chief Executive Officer | — | 2025-03-03 00:00:00 | D |
| 4 | 2500 | 3475 | — | Conversion of Exercise of derivative security at price 1.39 per share. | BERGMANN ANTHONY | Chief Financial Officer | — | 2025-03-03 00:00:00 | D |
| 5 | 750 | 1042 | — | Conversion of Exercise of derivative security at price 1.39 per share. | COLLIER EARL M JR | Director | — | 2025-02-27 00:00:00 | D |
| 6 | 3342 | — | — | Stock Award(Grant) at price 0.00 per share. | BERGMANN ANTHONY | Chief Financial Officer | — | 2025-01-02 00:00:00 | D |
| 7 | 8000 | 11120 | — | Conversion of Exercise of derivative security at price 1.39 per share. | KRASNEY KAREN | General Counsel | — | 2024-12-13 00:00:00 | D |
| 8 | 20391 | 22430 | — | Conversion of Exercise of derivative security at price 1.10 per share. | LITVACK FRANK I | Director | — | 2024-12-03 00:00:00 | I |
| 9 | 2798507 | 14999998 | — | Purchase at price 5.36 per share. | NIPPON SHINYAKU CO., LTD. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-09-20 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -43.23M | -24.73M | -29.65M | -21.06M |
| TotalUnusualItems | 2.09M | 1.72M | 487.27K | 367.71K |
| TotalUnusualItemsExcludingGoodwill | 2.09M | 1.72M | 487.27K | 367.71K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -40.47M | -22.29M | -29.02M | -20.02M |
| ReconciledDepreciation | 1.43M | 1.07M | 533.13K | 245.70K |
| EBITDA | -41.14M | -23.01M | -29.16M | -20.69M |
| EBIT | -42.56M | -24.08M | -29.70M | -20.94M |
| NormalizedIncome | -42.56M | -24.01M | -29.51M | -20.39M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -40.47M | -22.29M | -29.02M | -20.02M |
| TotalExpenses | 64.84M | 49.26M | 32.25M | 21.18M |
| TotalOperatingIncomeAsReported | -42.56M | -24.08M | -29.70M | -20.94M |
| DilutedAverageShares | 35.22M | 26.78M | 24.55M | 23.09M |
| BasicAverageShares | 35.22M | 26.78M | 24.55M | 23.09M |
| DilutedEPS | -1.15 | -0.83 | -1.18 | -0.87 |
| BasicEPS | -1.15 | -0.83 | -1.18 | -0.87 |
| DilutedNIAvailtoComStockholders | -40.47M | -22.29M | -29.02M | -20.02M |
| NetIncomeCommonStockholders | -40.47M | -22.29M | -29.02M | -20.02M |
| NetIncome | -40.47M | -22.29M | -29.02M | -20.02M |
| NetIncomeIncludingNoncontrollingInterests | -40.47M | -22.29M | -29.02M | -20.02M |
| NetIncomeContinuousOperations | -40.47M | -22.29M | -29.02M | -20.02M |
| PretaxIncome | -40.47M | -22.29M | -29.02M | -20.02M |
| OtherIncomeExpense | 2.10M | 1.79M | 677.85K | 915.92K |
| OtherNonOperatingIncomeExpenses | 7.47K | 67.66K | 190.58K | 548.21K |
| SpecialIncomeCharges | -112.81K | -6.04K | -34.27K | 310.25K |
| GainOnSaleOfPPE | -112.81K | -6.04K | -34.27K | -7.91K |
| OtherSpecialCharges | -318.16K | |||
| GainOnSaleOfSecurity | 2.20M | 1.73M | 521.53K | 57.46K |
| OperatingIncome | -42.56M | -24.08M | -29.70M | -20.94M |
| OperatingExpense | 64.84M | 49.26M | 32.25M | 21.18M |
| DepreciationAmortizationDepletionIncomeStatement | 651.23K | 442.37K | 112.55K | |
| DepreciationAndAmortizationInIncomeStatement | 651.23K | 442.37K | 112.55K | |
| DepreciationIncomeStatement | 651.23K | 442.37K | 112.55K | |
| ResearchAndDevelopment | 49.97M | 36.45M | 21.82M | 13.57M |
| SellingGeneralAndAdministration | 14.22M | 12.37M | 10.32M | 7.61M |
| GeneralAndAdministrativeExpense | 14.22M | 12.37M | 10.32M | 7.61M |
| OtherGandA | 3.61M | 3.19M | 3.38M | 2.73M |
| SalariesAndWages | 10.61M | 9.18M | 6.94M | 4.88M |
| TotalRevenue | 22.27M | 25.18M | 2.55M | 244.90K |
| OperatingRevenue | 22.27M | 25.18M | 2.55M | 244.90K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 45.58M | 31.15M | 25.24M | 24.19M |
| ShareIssued | 45.58M | 31.15M | 25.24M | 24.19M |
| TotalDebt | 1.45M | 2.24M | 2.56M | 2.87M |
| TangibleBookValue | 145.46M | 22.60M | 11.79M | 31.37M |
| InvestedCapital | 145.46M | 22.60M | 11.79M | 31.37M |
| WorkingCapital | 142.36M | 19.59M | 19.30M | 32.30M |
| NetTangibleAssets | 145.46M | 22.60M | 11.79M | 31.37M |
| CapitalLeaseObligations | 1.45M | 2.24M | 2.56M | 2.87M |
| CommonStockEquity | 145.46M | 22.60M | 11.79M | 31.37M |
| TotalCapitalization | 145.46M | 22.60M | 11.79M | 31.37M |
| TotalEquityGrossMinorityInterest | 145.46M | 22.60M | 11.79M | 31.37M |
| StockholdersEquity | 145.46M | 22.60M | 11.79M | 31.37M |
| GainsLossesNotAffectingRetainedEarnings | 1.03M | 235.81K | 105.24K | 0.00 |
| OtherEquityAdjustments | 1.03M | 235.81K | 105.24K | |
| RetainedEarnings | -199.83M | -159.37M | -137.08M | -108.06M |
| AdditionalPaidInCapital | 344.22M | 181.70M | 148.74M | 139.40M |
| CapitalStock | 45.58K | 31.15K | 25.24K | 24.18K |
| CommonStock | 45.58K | 31.15K | 25.24K | 24.18K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 25.02M | 36.13M | 38.31M | 9.96M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.99M | 4.86M | 14.72M | 5.83M |
| OtherNonCurrentLiabilities | 3.38M | 3.38M | 3.38M | 3.38M |
| NonCurrentDeferredLiabilities | 0.00 | 9.47M | 0.00 | |
| NonCurrentDeferredRevenue | 0.00 | 9.47M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 616.32K | 1.49M | 1.88M | 2.45M |
| LongTermCapitalLeaseObligation | 616.32K | 1.49M | 1.88M | 2.45M |
| CurrentLiabilities | 21.03M | 31.27M | 23.59M | 4.13M |
| CurrentDeferredLiabilities | 12.00M | 24.27M | 17.98M | 0.00 |
| CurrentDeferredRevenue | 12.00M | 24.27M | 17.98M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 834.80K | 749.11K | 682.04K | 417.63K |
| CurrentCapitalLeaseObligation | 834.80K | 749.11K | 682.04K | 417.63K |
| PayablesAndAccruedExpenses | 8.19M | 6.25M | 4.92M | 3.72M |
| Payables | 6.25M | 4.92M | ||
| DuetoRelatedPartiesCurrent | 27.48K | 89.23K | ||
| AccountsPayable | 6.22M | 4.83M | ||
| TotalAssets | 170.48M | 58.73M | 50.09M | 41.33M |
| TotalNonCurrentAssets | 7.10M | 7.88M | 7.21M | 4.89M |
| OtherNonCurrentAssets | 221.70K | 268.17K | 268.17K | 275.72K |
| GoodwillAndOtherIntangibleAssets | 0.00 | |||
| NetPPE | 6.87M | 7.61M | 6.94M | 4.62M |
| AccumulatedDepreciation | -3.45M | -2.21M | -1.18M | -756.71K |
| GrossPPE | 10.32M | 9.82M | 8.12M | 5.37M |
| Leases | 2.50M | 2.13M | 1.39M | 33.74K |
| OtherProperties | 7.63M | 7.50M | 6.59M | 5.30M |
| MachineryFurnitureEquipment | 192.08K | 188.00K | 139.34K | 43.12K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 163.39M | 50.86M | 42.89M | 36.44M |
| OtherCurrentAssets | 1.50M | 995.78K | 919.89K | 1.16M |
| PrepaidAssets | 1.16M | |||
| Receivables | 10.37M | 10.37M | 547.58K | 391.75K |
| AccountsReceivable | 10.37M | 10.37M | 547.58K | 391.75K |
| CashCashEquivalentsAndShortTermInvestments | 151.52M | 39.49M | 41.42M | 34.89M |
| OtherShortTermInvestments | 140.23M | 24.79M | 31.82M | 0.00 |
| CashAndCashEquivalents | 11.29M | 14.69M | 9.60M | 34.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -41.53M | -27.64M | 1.56M | -18.01M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 152.32M | 25.52M | 4.80M | 20.17M |
| CapitalExpenditure | -1.54M | -2.05M | -3.36M | -1.20M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 11.29M | 14.69M | 9.60M | 34.89M |
| BeginningCashPosition | 14.69M | 9.60M | 34.89M | 32.67M |
| ChangesInCash | -3.41M | 5.09M | -25.28M | 2.22M |
| FinancingCashFlow | 152.77M | 25.58M | 4.87M | 20.23M |
| CashFlowFromContinuingFinancingActivities | 152.77M | 25.58M | 4.87M | 20.23M |
| ProceedsFromStockOptionExercised | 450.17K | 64.60K | 70.30K | 50.56K |
| NetCommonStockIssuance | 152.32M | 25.52M | 4.80M | 20.17M |
| CommonStockIssuance | 152.32M | 25.52M | 4.80M | 20.17M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -116.18M | 5.11M | -35.07M | -1.20M |
| CashFlowFromContinuingInvestingActivities | -116.18M | 5.11M | -35.07M | -1.20M |
| NetInvestmentPurchaseAndSale | -114.64M | 7.16M | -31.71M | 0.00 |
| SaleOfInvestment | 93.80M | 104.60M | 82.51M | 0.00 |
| PurchaseOfInvestment | -208.44M | -97.44M | -114.22M | 0.00 |
| NetPPEPurchaseAndSale | -1.54M | -2.05M | -3.36M | -1.20M |
| PurchaseOfPPE | -1.54M | -2.05M | -3.36M | -1.20M |
| OperatingCashFlow | -40.00M | -25.60M | 4.92M | -16.81M |
| CashFlowFromContinuingOperatingActivities | -40.00M | -25.60M | 4.92M | -16.81M |
| ChangeInWorkingCapital | -10.78M | -11.75M | 28.75M | 263.67K |
| ChangeInOtherWorkingCapital | -12.27M | -3.18M | 27.45M | -81.33K |
| ChangeInOtherCurrentLiabilities | -81.33K | |||
| ChangeInOtherCurrentAssets | 0.00 | 7.55K | -187.02K | |
| ChangeInPayablesAndAccruedExpense | 1.94M | 1.33M | 1.21M | 991.17K |
| ChangeInPayable | 1.33M | 1.21M | 991.17K | |
| ChangeInAccountPayable | 1.33M | 1.21M | 991.17K | |
| ChangeInPrepaidAssets | -458.65K | -75.88K | 240.04K | -148.73K |
| ChangeInReceivables | 3.50K | -9.82M | -155.83K | -391.75K |
| OtherNonCashItems | -47.26K | -24.28K | 161.74K | 48.40K |
| StockBasedCompensation | 9.77M | 7.39M | 4.46M | 2.97M |
| AssetImpairmentCharge | 0.00 | -318.16K | ||
| DepreciationAmortizationDepletion | 1.43M | 1.07M | 533.13K | 245.70K |
| DepreciationAndAmortization | 1.43M | 1.07M | 533.13K | 245.70K |
| AmortizationCashFlow | 0.00 | 2.17K | ||
| AmortizationOfIntangibles | 0.00 | 2.17K | ||
| Depreciation | 1.43M | 1.07M | 533.13K | 243.53K |
| OperatingGainsLosses | 112.81K | 6.04K | 34.27K | 7.91K |
| GainLossOnSaleOfPPE | 112.81K | 6.04K | 34.27K | 7.91K |
| NetIncomeFromContinuingOperations | -40.47M | -22.29M | -29.02M | -20.02M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CAPR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|